Latest news

Lancement de la 10e édition du Challenge Qualité de Vie du Patient

Genialis advances biomarker discovery to reduce risk in cancer drug development targeting DNA damage response pathways

Swiss-based non-profit GARDP supports the development of Debiopharm’s new potential treatment for gonorrhoea

Vulgaroo remporte le 9e Challenge qualité de vie du patient avec un prix de 25’000 francs suisse

CARB-X Awards Additional Funding to Debiopharm for Continued Development of Early-Stage Antibiotic Targeting Drug-Resistant N. Gonorrhoeae Infections

Debiopharm to Showcase Research Results of Their First-In-Class Anti-Staphylococcal Program at IDWeek 2024 in Los Angeles

Debiopharm Recognizes Groundbreaking Japanese Cancer Research During the 83rd Annual Meeting of the Japanese Cancer Association

Debiopharm and WhiteLab Genomics announce a collaboration to advance drug target and design in Oncology

ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-Based Radiopharmaceutical Programs Targeting Solid Tumors